Chemomab Therapeutics (CMMB) Other financing activities (2018 - 2025)

Chemomab Therapeutics (CMMB) has 8 years of Other financing activities data on file, last reported at $121.0 million in Q3 2025.

• For the quarter ending Q3 2025, Other financing activities rose 4.31% year-over-year to $121.0 million; the trailing twelve-month figure through Sep 2025 stood at $121.0 million (up 4.31% YoY), and the FY2024 full-year result was $116.2 million, up 9.92% from the prior year.
• Other financing activities for Q3 2025 stood at $121.0 million, up from $117.7 million in the prior quarter.
• Across five years, Other financing activities topped out at $121.0 million in Q3 2025 and bottomed at -$14.2 million in Q4 2023.
• The 5-year median for Other financing activities is $103.8 million (2023), against an average of $61.9 million.
• Peak annual rise in Other financing activities reached 1817.39% in 2021, while the deepest fall reached 3163.64% in 2021.
• A 5-year view of Other financing activities shows it stood at -$1.0 million in 2021, then plunged by 793.37% to -$9.0 million in 2022, then sank by 56.75% to -$14.2 million in 2023, then jumped by 920.45% to $116.2 million in 2024, then rose by 4.15% to $121.0 million in 2025.
• The last three Other financing activities figures came in at $121.0 million (Q3 2025), $117.7 million (Q2 2025), and $116.3 million (Q1 2025), per Business Quant data.

Peer Comparison